Kymab Limited
USPTO PatentsView assignee record - 102 granted patents across 13 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).
The verdict
According to USPTO PatentsView, Kymab ranks #3,600 of 49,997 tracked US assignees by granted-patent volume, with 102 patents across 13 technology areas.
- #3,600
- of 49,997 US assignees by volume
- Top 14%
- by Innovation Score (50.0/100)
- 20.8
- avg claims per patent
- -35%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R3600 · Foreign Corporation #3,600 · 102 grants
GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL
- GRANTS-MID 102 grants
- TOP-DECILE #3,600/49,997
- PHOTO-FINISH H C Starck
- CPC-FOCUS C07K · 13 areas
- INNOV-PAR 50.0/100
- CLAIMS-DENSE 20.8 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DOWN -35% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: H.C. Starck Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Kymab’s 50.0 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Kymab
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Cardiovalve · near
Cardiovalve · near
50 score
- Centripetal Networks · near
Centripetal Networks · near
50 score
- Kymab · this assignee
Kymab · this assignee
50 score
- National Products · near
National Products · near
50 score
- REIFENHÄUSER & KG… · near
REIFENHÄUSER & KG… · near
50 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Kymab's Innovation Score is 50.0/100 (top 14% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Kymab?
Each dot is one of Kymab’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Kymab’s own 20.8 claims/patent is ABOVE the 15.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Kymab's grants concentrate
Kymab Limited is a focused PatentsView assignee: 13 CPC subclasses with 97.1% of grants classified under C07K (Peptides). Peak complete grant year is 2015 (23 grants) versus a trough of 3 in 2021. By volume, Kymab sits between H.C. Starck Inc. and Peking University Founder Group Co., Ltd..
Kymab's three-year grant acceleration
Kymab Limited shows 25 grants in 2022–2024 against only 19 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Kymab's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- H C Starck
H.C. Starck Inc.
102 patents
- Inficon
Inficon AG
102 patents
- Infineum Internat…
Infineum International Limited
102 patents
- Kakao
Kakao Corp.
102 patents
- Mellanox TLV
Mellanox Technologies TLV Ltd.
102 patents
- Nisshin Steel
Nisshin Steel Co., Ltd.
102 patents
- Ormco
Ormco Corporation
102 patents
- Peking University…
Peking University Founder Group Co., Ltd.
102 patents
- Kymab ◀
Kymab Limited
102 patents
What this shows Kymab holds 102 patents at rank #3,600, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Kymab
By rank, the assignees closest to #3,600 in granted patent volume.
- H.C. Starck Inc. #3,596 · 102 patents
- Inficon AG #3,597 · 102 patents
- Infineum International Limited #3,598 · 102 patents
- Kakao Corp. #3,599 · 102 patents
- Mellanox Technologies TLV Ltd. #3,601 · 102 patents
- Nisshin Steel Co., Ltd. #3,602 · 102 patents
- Ormco Corporation #3,603 · 102 patents
- Peking University Founder Group Co., Ltd. #3,604 · 102 patents
Leaders in C07K (Peptides)
Other assignees with the most granted patents in Kymab's primary technology class.
- The Regents of the University of California 894 in class
- Regeneron Pharmaceuticals, Inc. 824 in class
- Immatics Biotechnologies GmbH 678 in class
- Genentech, Inc. 565 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 513 in class
- The Trustees of the University of Pennsylvania 501 in class
- Novartis AG 407 in class
- The Board of Trustees of the Leland Stanford Junior University 400 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Kymab, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Kymab ranks #77 of 3,615 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (50 here).
Similar claim depth
Nearest assignees by average claims per patent (20.8 here).
Kymab's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
50 Top 14% higher than 86% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 23 | 22.5% |
| 2016 | 15 | 14.7% |
| 2017 | 6 | 5.9% |
| 2018 | 11 | 10.8% |
| 2019 | 5 | 4.9% |
| 2020 | 11 | 10.8% |
| 2021 | 3 | 2.9% |
| 2022 | 7 | 6.9% |
| 2023 | 12 | 11.8% |
| 2024 | 6 | 5.9% |
| 2025partial year | 3 | 2.9% |
Which technologies does Kymab Limited patent most?
Top 13 of 13 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Kymab Limited's patent record in context - here's where to go next.
- Kymab Limited's lead technology class is C07K (Peptides), 97.1% of its portfolio - see every assignee active in that class. Explore C07K
- Ranked #3,600 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Kymab Limited against H.C. Starck Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 50.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.